Invicta Diagnostic IPO

Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions. The company provides pathology and radiology testing, including imaging, radiology, and teleradiology, under the brand 'PC Diagnostics' through 7 diagnostic centres and a central laboratory across Mumbai, Maharashtra. Invicta Diagnostics Limited (trading as PC Diagnostics) is a Mumbai-based diagnostic services company specialising in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring: A flagship hub in Thane West offering full-spectrum pathology and advanced radiology (PET CT, MRI) Three additional hubs (Bhayandar, Byculla, Marol) providing specialised diagnostic services Three spokes in Lower Parel, Sewri, and Kalwa focused on basic imaging (X-ray, ultrasound) and sample collection. The company offers around 60 routine and 487 specialised pathology tests, plus about 96 basic and 130 advanced radiology tests. Invicta Diagnostics provides a comprehensive suite of diagnostic services, which includes: Routine Tests: Includes CBC, lipid profiles, liver function tests (LFT), kidney function tests (KFT), and thyroid panels Specialised Tests: Covers molecular diagnostics, immunoassays, infectious disease markers (e.g., dengue, COVID-19), cancer markers, and genetic panels Sample Collection Network: Invicta uses phlebotomists and collection partners to reach patients at home or through its spoke centres. As of October 31, 2025, the company employed 157 permanent employees. Competitive Strength: Expanding presence in the Mumbai Metropolitan Region (“MMR”), specifically in the radiology sector; A diagnostics provider that offers a one-stop solution at an affordable price. Technical capability and technology with IT infrastructure; Dedicated management team with significant industry experience; and Implementation of the Hub and Spoke Model.

Information on this page is for general awareness only and is not investment advice. Grey market premium (when shown) is unofficial and indicative. Always read the RHP/DRHP and consult a qualified adviser before investing.